Effect of oral rotavirus/iscom vaccines on immune responses in gnotobiotic lambs

Pinxteren, Laurens A.H. van; Bruce, M.; Campbell, Iain; Wood, Ann R.; Clarke, Christopher J.; Bellman, Anna; Morein, Brør; Snodgrass, D. R.

doi:10.1016/s0165-2427(99)00087-2

Cited by 20 publications

(10 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Following antigen injection into jejunal and ileal PP loops, specific antibody forming cells and antibody titer of the jejunal PP loops were both much higher than those of ileal PP loops. In addition, after oral injection of rotavirus/iscom vaccines, specific antibody was detected in jejunal PP of lambs [112]. Hence, the jejunal PP seems to be an efficient site for the induction of a mucosal immune response.…”

Section: Ileal and Jejunal Pp As The Site Of B-cell Selection And Thementioning

confidence: 94%

The sheep and cattle Peyer’s patch as a site of B-cell development

et al. 2006

View full text Add to dashboard Cite

-In sheep and cattle, the ileal Peyer's patch (PP), which extends one-two meters along the terminal small intestine, is a primary lymphoid organ of B-cell development. B-cell diversity in the ileal PP is thought to develop by combinatorial mechanisms, gene conversion and/or point mutation. These species also have jejunal PP that function more like secondary lymphoid tissues concerned with mucosal immune reactions. These two types of PP differ significantly in their histology, ontogeny and the extent of lymphocyte traffic. The prenatal development of follicles in the PP begins first in the jejunum during the middle of gestation and then in the ileum during late gestation. B-cells proliferate rapidly in the ileal PP follicle; up to five percent of these cells survive while the majority dies by apoptosis, perhaps driven by the influence of environmental antigen and/ or self-antigen. The surviving cells migrate from the ileal PP and populate the peripheral B-cell compartment. By adolescence, the ileal PP has involuted but the function of jejunal PP, compatible with a role as secondary lymphoid organ, continues throughout life. In this review, we focus on the development of PP as a site of B-cell repertoire generation, positive and negative B-cell selection, and the differences between ileal PP and jejunal PP.

show abstract

Section: Ileal and Jejunal Pp As The Site Of B-cell Selection And Thementioning

confidence: 94%

The sheep and cattle Peyer’s patch as a site of B-cell development

et al. 2006

View full text Add to dashboard Cite

show abstract

“…However, protection was either not obtained [80] or not evaluated [26]. Oral administration has been analyzed in pigs [96,153] and sheep [209] with rotavirus as the antigen and it resulted in good IgA responses with partial protection.…”

Section: Antigen-presenting Cell Targeting Mucosal Adjuvantsmentioning

confidence: 99%

“…This adjuvant can be mixed with antigens and when applied at a mucosa should have some of the advantages of ISCOM such as the preferential targeting of antigen presenting cells. The ISCOMATRIX has been analyzed in oral [209] and intranasal immunization in sheep [39] and in oral immunization in pigs [96] and it induced good mucosal IgA responses. However, the response obtained in sheep differed from that of an ISCOM vaccination in that the ISCOMATRIX induced a Th2-like response, whereas the ISCOM vaccine induced a mixed Th1-/Th2-like response.…”

Section: Antigen-presenting Cell Targeting Mucosal Adjuvantsmentioning

confidence: 99%

Adjuvants modulating mucosal immune responses or directing systemic responses towards the mucosa

et al. 2006

View full text Add to dashboard Cite

-In developing veterinary mucosal vaccines and vaccination strategies, mucosal adjuvants are one of the key players for inducing protective immune responses. Most of the mucosal adjuvants seem to exert their effect via binding to a receptor/or target cells and these properties were used to classify the mucosal adjuvants reviewed in the present paper: (1) ganglioside receptor-binding toxins (cholera toxin, LT enterotoxin, their B subunits and mutants); (2) surface immunoglobulin binding complex CTA1-DD; (3) TLR4 binding lipopolysaccharide; (4) TLR2-binding muramyl dipeptide; (5) Mannose receptor-binding mannan; (6) Dectin-1-binding ß 1,3/1,6 glucans; (7) TLR9-binding CpG-oligodeoxynucleotides; (8) Cytokines and chemokines; (9) Antigen-presenting cell targeting ISCOMATRIX and ISCOM. In addition, attention is given to two adjuvants able to prime the mucosal immune system following a systemic immunization, namely 1α, 25(OH) 2 D 3 and cholera toxin.

show abstract

“…The DBA/2 mice generated higher serum antibody titers than those obtained for BALB/c mice. Protection with VP6-based vaccines has also been obtained for rabbits (8) and gnotobiotic lambs (56). An exception is gnotobiotic pigs, which have not shown protection after vaccination with VP6-based vaccines given alone (62).…”

Section: Vol 17 2010 Bacillus Subtilis-based Rotavirus Vaccine 1651mentioning

confidence: 99%

“…The gnotobiotic pig may respond differently to certain rotavirus vaccines. For example, inactivated-whole-rotavirus vaccines given parenterally generated neutralizing antibody responses in gnotobiotic pigs but did not give protection (63), whereas protection was obtained after parenteral injection of inactivated rotavirus in rabbits (10) or gnotobiotic lambs (56). Protective neutralizing antibodies are directed against the two outer layer proteins, VP4 and VP7, proteins that are involved in viral attachment and entry into cells.…”

Section: Vol 17 2010 Bacillus Subtilis-based Rotavirus Vaccine 1651mentioning

confidence: 99%

Development of a Bacillus subtilis -Based Rotavirus Vaccine

Lee

Belitsky

Brinker

et al. 2010

Clin Vaccine Immunol

View full text Add to dashboard Cite

Bacillus subtilis vaccine strains engineered to express either group A bovine or murine rotavirus VP6 were tested in adult mice for their ability to induce immune responses and provide protection against rotavirus challenge. Mice were inoculated intranasally with spores or vegetative cells of the recombinant strains of B. subtilis. To enhance mucosal immunity, whole cholera toxin (CT) or a mutant form (R192G) of Escherichia coli heat-labile toxin (mLT) were included as adjuvants. To evaluate vaccine efficacy, the immunized mice were challenged orally with EDIM EW murine rotavirus and monitored daily for 7 days for virus shedding in feces. Mice immunized with either VP6 spore or VP6 vegetative cell vaccines raised serum anti-VP6 IgG enzymelinked immunosorbent assay (ELISA) titers, whereas only the VP6 spore vaccines generated fecal anti-VP6 IgA ELISA titers. Mice in groups that were immunized with VP6 spore vaccines plus CT or mLT showed significant reductions in virus shedding, whereas the groups of mice immunized with VP6 vegetative cell vaccines showed no difference in virus shedding compared with mice immunized with control spores or cells. These results demonstrate that intranasal inoculation with B. subtilis spore-based rotavirus vaccines is effective in generating protective immunity against rotavirus challenge in mice.

show abstract

Effect of oral rotavirus/iscom vaccines on immune responses in gnotobiotic lambs

Cited by 20 publications

References 40 publications

The sheep and cattle Peyer’s patch as a site of B-cell development

The sheep and cattle Peyer’s patch as a site of B-cell development

Adjuvants modulating mucosal immune responses or directing systemic responses towards the mucosa

Development of a Bacillus subtilis -Based Rotavirus Vaccine

Contact Info

Product

Resources

About